Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 7, 2014; 20(45): 16935-16947
Published online Dec 7, 2014. doi: 10.3748/wjg.v20.i45.16935
Published online Dec 7, 2014. doi: 10.3748/wjg.v20.i45.16935
Immunomodulatory therapies for acute pancreatitis
Jing Li, Lu-Ming Huang, Cheng-Wei Tang, Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Jing Li, Wen-Juan Yang, Cheng-Wei Tang, Division of Peptides Related with Human Diseases, Key Laboratory of Biotherapy of Human Diseases, Ministry of Education, Chengdu 610041, Sichuan Province, China
Author contributions: All the authors contributed equally to the manuscript.
Supported by National Natural Science Foundation of China, No. 81170384
Correspondence to: Cheng-Wei Tang, MD, PhD, Department of Gastroenterology, West China Hospital, Sichuan University, No. 37 Guoxuexiang, Wuhou District, Chengdu 610041, Sichuan Province, China. shcqcdmed@163.com
Telephone: +86-28-85422383 Fax: +86-28-85582944
Received: February 28, 2014
Revised: April 24, 2014
Accepted: May 26, 2014
Published online: December 7, 2014
Revised: April 24, 2014
Accepted: May 26, 2014
Published online: December 7, 2014
Core Tip
Core tip: In light of the complex immune system alterations that occur in acute pancreatitis (AP), it is necessary to develop more individualized interventions for AP patients by using immunomodulatory therapy instead of inflammatory drug monotherapy. We first suggest how we could monitor the immune status of these patients and identify optimal treatment methods. We also demonstrate for the first time that the detection of the genotypes of critical inflammatory mediators may be useful for screening populations of AP patients at high risk of severe infections.